Table 2. Association of sequence variants in or near ELL2 and TOM1.
| Populations | EAF |
MM |
MM+MGUS |
||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| ELL2—rs56219066-T | |||||
| Discovery | |||||
| Sweden/Norway | 0.732 | 1.20 (1.11–1.32) | 3.8 × 10−5 | 1.20 (1.11–1.32) | 3.8 × 10−5 |
| Iceland | 0.711 | 1.39 (1.17–1.64) | 1.1 × 10−4 | 1.32 (1.15–1.51) | 3.9 × 10−5 |
| Combined | 1.23 (1.14–1.33) | 6.5 × 10−8 | 1.23 (1.15–1.33) | 1.4 × 10−8 | |
| Replication | |||||
| Denmark (363/826) | 0.732 | 1.28 (1.04–1.57) | 0.017 | 1.28 (1.04–1.57) | 0.017 |
| Sweden (223/1285) | 0.735 | 1.30 (1.03–1.64) | 0.030 | 1.30 (1.03–1.64) | 0.030 |
| Combined | 1.29 (1.08–1.54) | 0.0046 | 1.29 (1.08–1.54) | 0.0046 | |
| Combined discovery and replication | 1.25 (1.16–1.34) | 9.6 × 10−10 | 1.24 (1.16–1.33) | 2.2 × 10−10 | |
| TOM1—rs138740-C | |||||
| Discovery | |||||
| Sweden/Norway | 0.364 | 1.20 (1.11–1.30) | 2.4 × 10−6 | 1.20 (1.11–1.30) | 2.4 × 10−6 |
| Iceland | 0.415 | 1.26 (1.09–1.46) | 0.0017 | 1.15 (1.03–1.30) | 0.015 |
| Combined | 1.22 (1.13–1.30) | 1.7 × 10−8 | 1.19 (1.11–1.27) | 1.3 × 10−7 | |
| Replication | |||||
| Denmark (352/815) | 0.360 | 1.08 (0.90–1.30) | 0.39 | 1.08 (0.90–1.30) | 0.39 |
| Sweden (235/1285) | 0.364 | 1.04 (0.85–1.26) | 0.72 | 1.04 (0.85–1.26) | 0.72 |
| Combined | 1.06 (0.93–1.21) | 0.38 | 1.06 (0.93–1.21) | 0.38 | |
| Combined discovery and replication | 1.18 (1.11–1.25) | 5.7 × 10−8 | 1.16 (1.10–1.23) | 2.7 × 10−7 | |
Abbreviations: CI, confidence interval; EAF, effect allele frequency; MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; OR, odds ratio.
Association results for ELL2 rs56219066 and TOM1 rs138740 in the discovery samples from Sweden, Iceland and Norway and in the replication samples from Sweden and Denmark. Logistic regression and meta-analysis P values indicated.